
The supply chain in the pharmaceutical industry acts as an invisible “lifeline,” connecting patients with products essential for their health and safety. The specific nature of these products means that any disruption—from a storage error to a delay or improper transport conditions—poses a risk to the patient. In the latest FM Logistic report, “Life on the Edge: Pharmaceutical Supply Chains Under Pressure – New Paths for Development,” experts analyze the condition of a sector that has had to undergo an accelerated operational resilience test in recent years.
The responsibility resting on participants in the pharmaceutical supply chain means it operates under constant pressure. It is no longer just timeliness that counts, but above all, the resilience of the system—its ability to adapt quickly. Today, competitive advantage is built by flexible, digitally supported, and sustainable models that allow for the maintenance of supply continuity even in an unpredictable environment.
Verification of operational models in the era of crisis
According to the FM Logistic report, recent years have exposed the weaknesses of traditional operational models. The most serious test was the COVID-19 pandemic, during which 70 percent of companies in the sector indicated significant gaps in their supply chains. Drug shortages, delays, and issues with order completeness became the impetus for profound changes, as a result of which companies began investing in system resilience, focusing on technology. Process automation, the development of specialized temperature-controlled packaging, and the construction of multi-channel distribution networks have become the standard. The pandemic also accelerated decisions to increase inventory levels and diversify supply sources.
The stability of global supply chains is also increasingly influenced by trade tensions between the USA and China. This conflict not only disrupts the flow of goods but also hits healthcare systems. Rising drug prices, hindered scientific cooperation, and delays in implementing innovations are just some of the consequences. An additional challenge is the high tariffs on the import of pharmaceutical products into the United States, including Chinese active pharmaceutical ingredients (APIs), which are used in about 40 percent of generic drugs on the US market. As a result, production costs are rising, and companies are forced to revise their strategies—from stockpiling to moving parts of testing and production closer to target markets.
Environmental challenges
At the same time, the pharmaceutical industry is facing increasing regulatory pressure regarding sustainable development, especially within the European Union. Pharmaceutical companies are now expected to provide not only high-quality products but also transparent and responsible supply chains.
Regulations in the pharmaceutical industry cover the entire supply chain, from production to the transport of active substances, and their key standards often vary by region. In Europe, oversight is provided by the European Medicines Agency (EMA), while licensing and inspections are the responsibility of national authorities. Regulations in Asia are more diverse, but they are united by strict control by most governments over the pharmaceutical sector and logistics service providers.
– explains Paweł Janicki, Senior Business Development Director at FM Logistic.
Digitalization and the role of logistics partners
As FM Logistic experts note, the supply chain in the pharmaceutical sector must constantly evolve, becoming more flexible, sustainable, and compliant with regulations. Companies are looking for partners who will realistically strengthen their operations. 3PL logistics service providers play a key role here, responsible for maintaining the integrity of drug shipments during long-distance transport.
The pharmaceutical industry appreciates the knowledge of operators who can transfer and implement best practices from other logistics sectors, such as consumer goods or e-commerce, for example, by developing hospital inventory planning services or handling the distribution of high-value drugs. The adaptation of proven solutions and the ability to react quickly to changes in the operational environment constitute a growing competitive advantage that will gain even greater importance in the future.
– says Paweł Janicki from FM Logistic.
Experts also point to the progress of digitalization and automation. Next-generation supply chains are increasingly relying on RFID and NFC technology, which streamline warehouse and distribution operations, enabling fast scanning and full product traceability. In turn, IoT solutions monitor location, temperature, humidity, or shocks in real-time, minimizing the risk of quality loss for drugs. In the coming years, it will be crucial to integrate data from sensors with AI analytics and robotics to automate processes, support inventory management, and enable immediate reaction to any deviations that could affect product quality.
Strategies for the future
The FM Logistic report clearly shows that strategies based on innovation, cooperation, and sustainable development will be key to the future of pharmaceutical supply chains. Investments in technology, strengthening relationships between market participants, and a proactive approach to regulations are becoming not an option, but a necessity. Companies that already treat digitalization, environmental responsibility, and operational flexibility as the foundation of their operations will not only be better prepared for future crises but will also build a lasting competitive advantage—in a sector where the stakes are the health and lives of patients.
The full report is available at https://www.fmlogistic.pl/publikowac/lancuchy-dostaw-farmaceutycznych-raport/
Source: FM Logistic Central Europe








